semaglutide united states An Ongoing Crisis: Shortage Raises Dual Concerns for Obesity and Diabetes Treatment Oral Semaglutide Gets FDA Approval
Description
07/15/25 Kirsty (insulin aspart-xjhz) New first-time interchangeable biosimilar approval July 15, 2025 - The FDA approved Biocon Biologics Kirsty (insulin aspart-xjhz), biosimilar and interchangeable to Novo Nordisks Novolog (insulin aspart)

If results are good and side effects manageable, theres no compelling reason to switch

Wegovy produced average weight reductions of 14.9% over 68 weeks in the STEP 1 trial and 15.2% in STEP 5

Zweite Bestellung, luft wieder reibunsglos durch

This 52-week trial focused on patients who had similar issues but were already on PAP therapy
